首页> 外文期刊>mSystems >Bacteroides fragilis Strain ZY-312 Defense against Cronobacter sakazakii-Induced Necrotizing Enterocolitis In Vitro and in a Neonatal Rat Model
【24h】

Bacteroides fragilis Strain ZY-312 Defense against Cronobacter sakazakii-Induced Necrotizing Enterocolitis In Vitro and in a Neonatal Rat Model

机译:脆弱拟杆菌(Bacteroides fragilis)菌株ZY-312在体外和在新生大鼠模型中对抗阪崎肠杆菌(cronobacter sakazakii)诱导的坏死性小肠结肠炎的防御

获取原文
           

摘要

Cronobacter sakazakii is an important pathogen associated with the development of necrotizing enterocolitis (NEC), infant sepsis, and meningitis. Several randomized prospective clinical trials demonstrated that oral probiotics could decrease the incidence of NEC. Previously, we isolated and characterized a novel probiotic, Bacteroides fragilis strain ZY-312. However, it remains unclear how ZY-312 protects the host from the effects of C. sakazakii infection. To understand the underlying mechanisms triggering the probiotic effects, we tested the hypothesis that there was cross talk between probiotics/probiotics-modulated microbiota and the local immune system, governed by the permeability of the intestinal mucosa, using in vitro and in vivo models for the intestinal permeability. The probiotic effects of ZY-312 on intestinal epithelial cells were first examined, and the results revealed that ZY-312 inhibited C. sakazakii invasion, C. sakazakii -induced dual cell death (pyroptosis and apoptosis), and epithelial barrier dysfunction in vitro and in vivo . The presence of ZY-312 also resulted in decreased expression of an inflammasome (NOD-like receptor family member pyrin domain-containing protein 3 [NLRP3]), caspase-3, and serine protease caspase-1 in a neonatal rat model. Furthermore, ZY-312 significantly modulated the compositions of the intestinal bacterial communities and decreased the relative abundances of Proteobacteria and Gammaproteobacteria but increased the relative abundances of Bacteroides and Bacillus in neonatal rats. In conclusion, our findings have shown for the first time that the probiotic B. fragilis ZY-312 suppresses C. sakazakii -induced NEC by modulating the proinflammatory response and dual cell death (apoptosis and pyroptosis). IMPORTANCE Cronobacter sakazakii is an opportunistic pathogenic bacterium that can cause necrotizing enterocolitis (NEC). However, the mechanism of pathogenicity of C. sakazakii is largely unknown. Here we have now demonstrated that apoptotic and pyroptotic stimuli are effectors of C. sakazakii -induced NEC. Previously, we isolated a novel probiotic strain candidate from fecal samples from healthy infants and characterized it as Bacteroides fragilis strain ZY-312. Functional characterization reveals that ZY-312 inhibited C. sakazakii invasion, restoring epithelial barrier dysfunction, decreasing the expression of inflammatory cytokines, and reducing dual cell death (pyroptosis and apoptosis). Furthermore, the presence of ZY-132 was sufficient to hinder the adverse reaction seen with C. sakazakii in a C. sakazakii -induced NEC model. Taking the results together, our study demonstrated the utility of ZY-312 as a promising probiotic agent for the prevention of NEC.
机译:阪崎肠杆菌是与坏死性小肠结肠炎(NEC),婴儿败血症和脑膜炎相关的重要病原体。几项随机的前瞻性临床试验表明,口服益生菌可以降低NEC的发生率。以前,我们分离并鉴定了新型益生菌脆弱拟杆菌(Bacteroides fragilis)菌株ZY-312。但是,尚不清楚ZY-312如何保护宿主免受阪崎肠杆菌感染的影响。为了了解触发益生菌作用的潜在机制,我们使用了体外和体内模型,对以下假设进行了检验:益生菌/益生菌调节的微生物群与局部免疫系统之间存在串扰,该相互作用受肠粘膜通透性的控制。肠道通透性。首先检查了ZY-312对肠道上皮细胞的益生菌作用,结果表明ZY-312在体外和体外抑制了阪崎肠杆菌的入侵,阪崎肠杆菌诱导的双细胞死亡(pyroptosis和凋亡)以及上皮屏障功能障碍。体内。 ZY-312的存在还导致新生大鼠模型中炎性小体(含NOD的受体家族成员含吡啶结构域的蛋白质3 [NLRP3]),caspase-3和丝氨酸蛋白酶caspase-1的表达降低。此外,ZY-312显着调节了肠道细菌群落的组成,降低了变形杆菌和γ-变形杆菌的相对丰度,但增加了拟杆菌和芽孢杆菌在新生大鼠中的相对丰度。总之,我们的发现首次表明,益生菌脆弱型芽孢杆菌ZY-312通过调节促炎反应和双细胞死亡(凋亡和发烧)来抑制阪崎肠杆菌诱导的NEC。重要事项阪崎肠杆菌是一种机会致病性细菌,可导致坏死性小肠结肠炎(NEC)。然而,阪崎肠杆菌的致病性机制很大程度上未知。在这里,我们现在已经证明,凋亡和焦磷酸刺激是阪崎肠杆菌诱导的NEC的效应子。以前,我们从健康婴儿的粪便样本中分离出了一种新型的益生菌菌株,并将其表征为脆弱的拟杆菌(Bacteroides fragilis)ZY-312。功能表征显示ZY-312抑制了阪崎肠梭菌的入侵,恢复了上皮屏障功能障碍,降低了炎性细胞因子的表达,并减少了双细胞死亡(pyroptosis和凋亡)。此外,ZY-132的存在足以阻碍在阪崎肠杆菌诱导的NEC模型中阪崎肠杆菌看到的不良反应。综合这些结果,我们的研究证明ZY-312作为预防NEC的有前途的益生菌制剂的实用性。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号